التفاصيل البيبلوغرافية
| العنوان: |
Activated interferon response, from DNA damage in multiple myeloma cells contributes to the chemotherapeutic effects of anthracyclines. |
| المؤلفون: |
Jin Li, Zhuxia Jia, Rongxuan Wang, Bitao Xiao, Yanan Cai, Tianshu Zhu, Weiya Wang, Xinyue Zhang, Shu Fan, Xiaolong Fan, Wenmin Han, Xuzhang Lu |
| المصدر: |
Frontiers in Oncology; 2024, p1-9, 9p |
| مصطلحات موضوعية: |
MULTIPLE myeloma, ANTHRACYCLINES, DNA damage, INTERFERONS, CANCER chemotherapy, PLASMA cell diseases, CD38 antigen, PLASMACYTOMA |
| مستخلص: |
Introduction: Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells in bone marrow. Upfront identification of tumor subgroups with specific biological markers has the potential to improve biologically-driven therapy. Previously, we established a molecular classification by stratifying multiple myeloma into two subtypes with a different prognosis based on a gene module co-expressed with MCL-1 (MCL1-M). Methods: Gene Ontology (GO) analysis with differentially expressed genes was performed to identify signal pathway. Drug sensitivity was analyzed using the OncoPredict algorithm. Drug sensitivity of different myeloma cell lines was detected by CCK8 and flow cytometry. RNA-seq was performed on drugsensitive cell lines before and after adriamycin treatment. RT-qPCR was used to further verify the sequencing results. The expression of g-H2AX and dsDNA in sensitive and resistant cell lines was detected by immunofluorescence method. Results: In our study, we demonstrated that MCL1-M low MM were more sensitive to anthracyclines. We treated different myeloma cell lines with doxorubicin in vitro and discovered the association of drug sensitivity with IFN signaling. Herein, we demonstrate that the doxorubicin-sensitive myeloma cell line showed significant DNA damage and up-regulated expression of genes related to the IFN response, which was not observed in drug-insensitive cell lines. Discussion: Our results suggest that the active IFN signaling pathway may serve as a marker for predicting chemotherapy sensitivity in patients with myeloma. With our MCL1-M molecular classification system, we can screen patients with a potentially good response to the interferon signaling pathway and provide individualized treatment for MM. We propose IFN-a as adjuvant therapy for patients with myeloma sensitive to anthracyclines to further improve the therapeutic effect and prolong the survival of patients. [ABSTRACT FROM AUTHOR] |
|
Copyright of Frontiers in Oncology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder